Edward A Dennis Selected Research

Eicosanoids

1/2020	Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis.
1/2019	Directed Non-targeted Mass Spectrometry and Chemical Networking for Discovery of Eicosanoids and Related Oxylipins.
1/2019	Phospholipase A2 catalysis and lipid mediator lipidomics.
1/2019	AMP-activated protein kinase activation ameliorates eicosanoid dysregulation in high-fat-induced kidney disease in mice.
10/2017	Borrelia burgdorferi infection induces lipid mediator production during Lyme arthritis.
11/2016	Liberating Chiral Lipid Mediators, Inflammatory Enzymes, and LIPID MAPS from Biological Grease.
10/2016	Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A2.
10/2016	2-Oxoamide inhibitors of cytosolic group IVA phospholipase A2 with reduced lipophilicity.
8/2015	Eicosanoid storm in infection and inflammation.
1/2015	Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edward A Dennis Research Topics

Disease

27	Inflammation (Inflammations) 01/2022 - 04/2005
7	Hyperalgesia 12/2018 - 04/2005
7	Atherosclerosis 01/2013 - 03/2002
6	Neoplasms (Cancer) 06/2020 - 06/2009
6	Infections 08/2015 - 08/2009
4	Autoimmune Diseases (Autoimmune Disease) 01/2019 - 05/2009
4	Pain (Aches) 01/2016 - 08/2007
3	Obesity 01/2022 - 10/2012
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2013
3	Fibrosis (Cirrhosis) 01/2020 - 12/2017
3	Non-alcoholic Fatty Liver Disease 01/2020 - 01/2015
3	Lyme Disease (Disease, Lyme) 10/2017 - 08/2009
3	Disease Progression 11/2016 - 05/2009
2	Insulin Resistance 01/2022 - 03/2010
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 01/2022
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020 - 12/2017
2	Demyelinating Diseases (Demyelinating Disease) 12/2011 - 05/2009
2	Arthritis (Polyarthritis) 08/2009 - 06/2009
1	Chronic Disease (Chronic Diseases) 01/2022
1	Dyslipidemias (Dyslipidemia) 01/2020
1	Superinfection 01/2020
1	Zika Virus Infection 01/2020
1	Anemia 01/2020
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2019
1	Kidney Diseases (Kidney Disease) 01/2019
1	Nervous System Diseases (Neurological Disorders) 01/2019
1	Neuralgia (Stump Neuralgia) 12/2018
1	Nociceptive Pain 12/2018
1	Wounds and Injuries (Trauma) 12/2017
1	Bacterial Infections (Bacterial Infection) 10/2017
1	Asthma (Bronchial Asthma) 01/2017
1	Fever (Fevers) 01/2016
1	Carcinogenesis 11/2014
1	Experimental Arthritis 09/2014
1	Skin Neoplasms (Skin Cancer) 06/2014
1	Thrombosis (Thrombus) 05/2014
1	Human Influenza (Influenza) 07/2013

Drug/Important Bio-Agent (IBA)

19	EicosanoidsIBA 01/2020 - 06/2009
17	LipidsIBA 01/2022 - 06/2009
11	EnzymesIBA 01/2022 - 05/2006
8	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2019 - 04/2005
7	Phospholipases (Phospholipase)IBA 06/2020 - 05/2006
6	Arachidonic Acid (Vitamin F)IBA 01/2020 - 12/2011
6	Biomarkers (Surrogate Marker)IBA 01/2020 - 06/2011
5	Phospholipases A2 (Phospholipase A2)IBA 01/2019 - 04/2005
5	ProstaglandinsIBA 01/2016 - 08/2011
5	CarrageenanIBA 05/2013 - 04/2005
4	oxidized low density lipoproteinIBA 01/2013 - 03/2002
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 11/2011
3	Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)IBA 12/2018 - 05/2013
3	Masoprocol (Actinex)FDA Link 12/2018 - 08/2010
3	Phospholipids (Phosphatides)FDA LinkGeneric 10/2016 - 05/2009
3	Dinoprostone (PGE2)FDA Link 11/2014 - 01/2006
3	Lipoproteins (Lipoprotein)IBA 05/2014 - 10/2010
3	Arachidonate 12-Lipoxygenase (12 Lipoxygenase)IBA 05/2013 - 08/2010
3	LDL Lipoproteins (beta Lipoproteins)IBA 01/2013 - 03/2002
3	Calcium-Independent Phospholipases A2IBA 05/2009 - 05/2006
2	Eicosapentaenoic AcidIBA 01/2020 - 01/2016
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2020 - 01/2015
2	CytokinesIBA 01/2019 - 01/2014
2	Pharmaceutical PreparationsIBA 12/2018 - 09/2014
2	Formaldehyde (Formol)FDA Link 12/2018 - 04/2005
2	LipopolysaccharidesIBA 12/2018 - 12/2011
2	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2017 - 12/2005
2	Lipoxygenase (Lipoxygenase-1)IBA 10/2016 - 01/2016
2	Messenger RNA (mRNA)IBA 03/2015 - 04/2005
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 11/2014 - 06/2014
2	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 01/2013 - 06/2011
2	CholesterolIBA 09/2012 - 10/2010
2	Nonesterified Fatty Acids (NEFA)IBA 12/2011 - 05/2009
2	LysophospholipidsIBA 12/2011 - 05/2009
1	Phosphatidylinositols (Phosphatidylinositol)IBA 06/2020
1	adrenic acid (7,10,13,16-docosatetraenoic acid)IBA 01/2020
1	LigandsIBA 01/2020
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2020
1	SphingolipidsIBA 01/2020
1	Hydroxyeicosatetraenoic Acids (HETE)IBA 01/2020
1	CeramidesIBA 01/2020
1	12-Hydroxy-5,8,10,14-eicosatetraenoic AcidIBA 01/2020
1	11,12-dihydroxyeicosatrienoic acidIBA 01/2020
1	CollagenIBA 01/2020
1	OxylipinsIBA 01/2019
1	LipoxygenasesIBA 01/2019
1	AMP-Activated Protein KinasesIBA 01/2019
1	CytochromesIBA 01/2019
1	Lipid AIBA 12/2018
1	Carbon Tetrachloride (Tetrachloromethane)IBA 12/2017
1	Cytochrome P-450 CYP2E1 (CYP2E1)IBA 12/2017
1	Hyaluronic Acid (Hyaluronan)IBA 01/2017
1	Antiviral Agents (Antivirals)IBA 01/2017
1	Inflammation MediatorsIBA 11/2016
1	Docosahexaenoic AcidsIBA 01/2016
1	Methotrexate (Mexate)FDA LinkGeneric 09/2014
1	Etanercept (Enbrel)FDA Link 09/2014
1	ChemokinesIBA 01/2014
1	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 07/2013
1	Linoleic Acid (Linoleate)IBA 07/2013
1	9-hydroxyoctadecadienoic acidIBA 07/2013

Therapy/Procedure

3	Therapeutics 12/2018 - 06/2011
1	Ligation 12/2017